Author:
Song Lin,Zhang Ni,Jiang Ting-ting,Jia Yuntao,Liu Yao
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Shirkey HC. Therapeutic orphans–everybody’s business. Ann Pharmacother. 2006;40(6):1174.
2. Domingues C, Jarak I, Veiga F, Dourado M, Figueiras A. Pediatric drug development: reviewing challenges and opportunities by tracking innovative therapies. Pharmaceutics. 2023;15(10):2431.
3. Ward RM, Benjamin DK, Davis JM, Gorman RL, Kauffman R, Kearns GL, et al. The need for pediatric drug development. J Pediatr. 2018;192:13–21.
4. Ueyama E, Kaneko M, Narukawa M. Pediatric drug development in Japan: a comparison of the current situation and characteristics between Japan and Europe. Therap Innov Regul Sci. 2020;54:1152–8.
5. National Health and Family Planning Commission, National Development and Reform Commission, Ministry of Industry and Information Technology, Ministry of Human Resources and Social Security, China Food and Drug Administration, National Administration of Traditional Chinese Medicine. Several opinions on safeguarding medication for children. 2014. Available from: http://www.nhc.gov.cn/yaozs/s3581/201405/e51354d631944fa68aac0c4d9585f291.shtml. Accessed 29 Jan 2024.